cs-0777

CS-0777 is a potent, selective, and orally active small molecule prodrug that acts as an agonist of the sphingosine 1-phosphate receptor 1 (S1PR1). After oral administration, it is phosphorylated in vivo to its active metabolite (CS-0777-P), which selectively modulates S1PR1. This mechanism leads to immunosuppressive effects by reducing circulating lymphocytes through sequestration in lymphoid tissues. The drug was developed primarily for the treatment of multiple sclerosis and has demonstrated efficacy in preclinical models of autoimmune diseases such as experimental autoimmune encephalomyelitis. Compared to other S1P modulators like fingolimod, CS-0777 shows greater selectivity for S1PR1 over S1P3, potentially reducing off-target side effects. The compound was discovered and developed by Daiichi Sankyo[2][3][5][6].

Other names

CS-0777PCS0777PCS 0777P